Pravastatin: A Review of its Pharmacological Properties and Therapeutic Potential in Hypercholesterolaemia

Drugs

Volumn 42, Issue 1, 1991, Pages 65-89

  McTavish, Donna ^a   Sorkin, Eugene M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN; BEZAFIBRATE; CHOLESTEROL; CLINOFIBRATE; COLESTIPOL; COLESTYRAMINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; MEVINOLIN; PLACEBO; PRAVASTATIN; PROBUCOL; SIMVASTATIN;

CLINICAL ARTICLE; CONTROLLED STUDY; GASTROINTESTINAL DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RASH; REVIEW;

ANIMAL; ANTICHOLESTEREMIC AGENTS; HUMAN; HYPERCHOLESTEROLEMIA; PRAVASTATIN;

EID: 0025830289     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/00003495-199142010-00005     Document Type: Article

References (85)

1. HMG-CoA reductase inhibitors: the development
2. Effects of HMG CoA reductase inhibitors on cholesterol synthesis
3. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase and a cholesterol-lowering agent
4. Pravastatin sodium (CS-514), a novel cholesterol-lowering agent which inhibits HMG-CoA reductase
5. Efficacy of pravastatin and bezafibrate in primary hypercholesterolaemia
6. Changes in lipoprotein particles defined by their apolipoprotein composition on pravastatin or cholestyramine therapy
7. ’REGRESS’: a trial to assess the lipid lowering effects of pravastatin in normocholesterolemic men with myocardial ischemia
8. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolaemia heteroxygotes
9. Multivalent feedback regulation of HMG-CoA reductase, a control mechanism coordinating isoprenoid synthesis and cell growth
10. Lipoprotein receptors in the liver control signals for plasma cholesterol traffic
11. Pravastatin vs gemfibrozil in the treatment of primary hypercholesterolemia. The Italian Multicenter Pravastatin Study I
12. Is reduced vitamin D synthesis a complication of treatment with HMG CoA reductase inhibitors? Abstract
13. ML-236A, ML-236B and ML-236C, new inhibitors of cholesterogenesis produced by Penicillium citrium
14. Plasma lipoprotein changes after treatment with pravastatin and gemfibrozil in patients with familial hypercholesterolaemia
15. Fat transport in lipoproteins: an integrated approach to mechanisms and disorders
16. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia
17. Tissue selectivity of the cholesterol-lowering agents lovastatin, simvastatin and pravastatin in rats in vivo
18. Study on clinical efficacy of CS-514 (pravastatin) in long-term treatment on hypercholesterolemia
19. Clinical usefulness of pravastatin (CS-514) in the treatment of patients with hyperlipemia: double-blind comparison with probucol
20. Clinical evaluation of CS-514 (pravastatin) on hyperlipidemia: double blind study with clinofibrate
21. Pravastatin: a hydrophilic inhibitor of cholesterol synthesis
22. Cholesterol metabolism in man
23. The effect of pravastatin in relation to low density lipoprotein receptor activity
24. Lovastatin: a preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia
25. The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia
26. Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia
27. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia I. A dose-response study
28. Efficacy and safety of pravastatin in patients with primary hypercholesterolemia II. Once-daily versus twice-daily dosing
29. The effects of CS-514 (pravastatin), an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, on serum lipids and steroid hormones in the hypercholesterolemic elderly
30. Once-daily pravastatin in patients with primary hypercholesterol: a dose-response study
31. Effects of CS-514 on biliary lipid metabolism in patients with hyperlipidemia
32. Effects of CS-514, a new inhibitor of HMG CoA reductase, on plasma lipids, lipoproteins and apoproteins in patients with primary hypercholesterolemia
33. Effects of 6-month treatment with eptastatin (CS-514) on plasma lipoproteins and apolipoproteins in nonfamilial hypercholesterolemia
34. Tissue-selective inhibition of cholesterol synthesis in vivo by pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
35. A comparison of pravastatin (CS-514) and colestyramine therapy for patients with heterozygous familial hypercholesterolemia
36. Long term combination therapy of primary hypercholesterolemia with pravastatin. Abstract 0513
37. Induction of mRNA for low-density lipoprotein receptors in heterozygous Watanabe heritable hyperlipidemic rabbits treated with CS-514 (pravastatin) andxholestyramine
38. The Lipid Research Clinic’s Coronary Primary Prevention Trial. Results I. Reduction in medicine of coronary heart disease
39. The Lipid Research Clinic’s Coronary Primary Prevention Trial. Results II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
40. Effects of CS-514 on serum lipoprotein lipid and apolipoprotein levels in patients with familial hypercholesterolemia
41. Differential transport of pravastatin and lovastatin by hepatocytes and fibroblasts. Abstract 0023
42. Differences in the response to pravastatin treatment between familial and non-familial hypercholesterolaemic patients
43. Tissue-selective acute effects of inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A reductase on cholesterol biosynthesis in lens
44. Significance of combined treatment with pravastatin, probucol, and cholestylamine for cholesterol reduction and xanthoma regression in patients with familial hypercholesterolemia. Abstract 795
45. Effect of CS514 on hypercholesterolemic patients
46. The effect of CS-514, an inhibitor of HMG-CoA reductase, on serum lipids in healthy volunteers
47. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects
48. Safety of pravastatin in long-term clinical trials conducted in the United States
49. Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia
50. Comparative pharmacokinetics and pharmacodynamics of pravastatin and lovastatin
51. Excretion of pravastatin, an HMG CoA reductase inhibitor, in breast milk of lactating women
52. The clinical pharmacology of SQ 31,000 (CS 514) in healthy subjects
53. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): design features and recruitment statistics of a US multicenter quantitative angiographic trial of lipid-lowering. Abstract
54. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol
55. Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514). in hypercholesterolemic subjects: a double blind test
56. Long-term effect of CS-514 (HMG-CoA reductase inhibitor) on serum lipids, lipoproteins, and apolipoproteins in patients with hypercholesterolemia
57. Phase I study of CS-514, an inhibitor of HMG-CoA reductase II: Pharmacokinetics of CS-514 in healthy volunteers
58. Comparison of the efficacy of pravastatin and cholestyramine in hypercholesterolaemic patients
59. Hydrophilicity and the differential pharmacology of pravastatin
60. Effects of pravastatin (CS-514) by long-term administration in patients with hyperlipidemia
61. Suppression of established atherosclerosis and xanthomas in mature WHHL rabbits by keeping their serum cholesterol levels extremely low
62. Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects
63. Simvastatin: a review of its pharmacological properties and therapeutic potential in hypercholesterolaemia
64. CS-514, a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase: tissue-selective inhibition of sterol synthesis and hypolipidemic effect on various animal species
65. Lovastatin therapy in receptor-negative homozygous familial hypercholesterolaemia. Lack of effect on low-density lipoprotein concentrations or turnover
66. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apoliproprotein B-containing lipoproteins
67. Preventive effect of pravastatin sodium, a potent inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on coronary atherosclerosis and xanthoma in WHHL rabbits
68. Treatment of familial hypercholesterolaemia: a controlled trial of the effects of pravastatin or cholestyramine therapy on lipoprotein and apolipoprotein levels
69. Effects of CS-514 (pravastatin) on serum lipid levels of the patients with hypercholesterolemia
70. Yoshino G, Kazumi T, Inui A, Iwatani I, Yokoni K, et al. Probucol versus eptastatin in hypercholesterolaemic diabetics. Lancet: 740–741, 1986c
71. Effects of CS-514 on plasma lipids and lipoprotein composition in hypercholesterolemic subjects
72. Long-term treatment of hypercholesterolemic non-insulin dependent diabetics (NIDDM) with pravastatin (CS-514)
73. Effect of CS-514 (pravastatin) on VLDL-triglyceride kinetics in rats
74. Effect of CS-514, an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on lipoprotein and apolipoprotein in plasma of hypercholesterolemic diabetics
75. Comparison of the effects of pravastatin and simvastatin in hypercholesterolemic subjects
76. Effect of eptastatin (CS-514) on hypercholesterolemic patients. Comparison with probucol
77. Two-year study on the effect of pravastatin (CS-514) on plasma lipoprotein and apolipoprotein concentrations in hypercholesterolemic patients